Comparative study of effect of Withania somnifera as an adjuvant to DOTS in patients of newly diagnosed sputum smear positive pulmonary tuberculosis
Kumar R, Rai J, Kajal NC, Devi P
The Indian journal of tuberculosis · 9 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2017-05-21 · Indian J Tuberc · vol. 65 · número 3 · págs. 246–251
- Editorial
- Elsevier BV
- Citado
- 23 citas · más que el 83% de estudios similares · 1.8× el promedio de su campo
- Referencias
- 29 trabajos
- Acceso
- De pago
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Tuberculosis Research and Epidemiology · Infectious Diseases and Tuberculosis
- Palabras clave
- Withania somnifera, pulmonary tuberculosis, smear-positive tuberculosis, DOTS, adjuvant therapy, immunomodulation, sputum conversion, CD4 and CD8 lymphocytes, liver enzymes, serum uric acid, health-related quality of life, herbal medicine
- MeSH
- sputum, humans, withania, plant roots, tuberculosis, pulmonary, plant extracts, antitubercular agents, treatment outcome, phytotherapy, drug therapy, combination, double-blind method, quality of life, adolescent, adult, aged, middle aged, female, male, young adult
4 autores
- Ranjeet Kumar🇮🇳 · autor de correspondenciaGovernment Medical College, Amritsar
- Jaswant Rai🇮🇳Government Medical College, Amritsar
- Nirmal Chand Kajal🇮🇳Government Medical College, Amritsar
- Pushpa Devi🇮🇳Government Medical College, Amritsar
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Ashwagandha (Withania somnifera Linn.) a rejuvenative herb has long been used as an immunomodulator in Indian subcontinent. As immunity plays an important role in pathogenesis and treatment of tuberculosis (TB), so role of W. somnifera as an adjuvant has been studied on selected parameter.
Method
A randomized, double-blind placebo-control study was conducted in two groups of 60 newly diagnosed sputum smear positive pulmonary TB patients on Directly Observed Treatment - short course (DOTS) regime. W. somnifera root extract or placebo capsules were given as add-on therapy for duration of 12 weeks. Effects on sputum conversion, Hemoglobin (Hb), body weight, Erythrocyte Sedimentation Rate (ESR), RBC counts, WBC counts, CD4 and CD8 counts, Serum Glutamic-Oxaloacetic Transaminase (SGOT), Serum Glutamic-Pyruvic Transaminase (SGPT), serum uric acid and HRQL (Health Related Quality of Life) Index scores were studied.
Results
At the end of 8 weeks, sputum conversion was seen in 86.6% patients in study group and 76.6% in placebo group. At the end of 12 weeks a highly significant increase was seen in both CD4 and CD8 counts in study group. A raised SGOT and SGPT levels (>35IU/L) were observed in 16.6% and 33.3% patients in study group; 43.33% and 53.33% in the placebo group of patients. Elevated serum uric acid levels (>6mg/dl) were observed in 20% and 33.33% in study and placebo group respectively. Average gain in HRQL score was better in patients of study group.
Conclusion
Use of W. somnifera as an adjuvant in conjunction with anti-TB drugs used as DOTS showed a favorable effect on symptoms and immunological parameters in patients with pulmonary TB.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.